<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653549</url>
  </required_header>
  <id_info>
    <org_study_id>01169</org_study_id>
    <nct_id>NCT00653549</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Torsemide Tablets Under Fasting Conditions</brief_title>
  <official_title>Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Par Torsemide Tablets 20mg With That of Roche Demadex 1*20 mg in Healthy Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anapharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the single-dose bioavailability of Torsemide tablets with Demadex
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the single -dose bioavailability of Par Torsemide tablets 20mg with that Roche
      Demadex 1*20mg tablets under fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">May 2001</completion_date>
  <primary_completion_date type="Actual">May 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>To Determine Bioequivalence Under Fasting Conditions</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Par formulated product under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received Roche formulated product under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torsemide</intervention_name>
    <description>Tablets, 20 mg, single-dose</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Demadex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Demadex</intervention_name>
    <description>tablets, 20 mg, single-dose</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Torsemide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects enrolled in the study will be members of the community at large.

          -  The Recruitment will be done by radio, newspapers and Anapharm Inc.

          -  Anapharm Website advertisements.

          -  Subjects must meet all the following criteria in order to be included in the study.

          -  Subjects will be male and / or female, smokers and non-smokers, 18 years of age and
             older.

          -  Subjects should read, sign, and date an Informed Consent form prior to the study
             procedures.

          -  Subjects must complete all screening procedures within 28 days prior to the
             administration of the study medication.

        Exclusion Criteria:

          -  Breast- feeding female subjects.

          -  Any clinically significant abnormality found during medical screening.

          -  Subjects with BMI â‰¥30

          -  Any Clinically significant gastrointestinal pathology (e.g. chronic diarrhea,
             inflammatory bowel diseases) or unresolved gastrointestinal symptoms (e.g. diarrhea,
             vomiting), susceptible of interfering with the absorption of drugs.

          -  Clinically significant illness within 4 weeks prior to the administration of the study
             medication

          -  Abnormal laboratory tests judged clinically significant.

          -  ECG abnormalities (clinically significant) (PR interval greater than 225ms);or vital
             sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic
             blood pressure lower than 60 or over 95 mmHg, or heart rate less than 60 bpm) at
             screening.

          -  History of allergic reactions to torsemide or sulfonylureas (e.g. tolbutamide,
             chlorpropamide, glyburide and gliclazide) or other related drugs ( e.g. furosemide,
             bumetanide, sulfabenzamide, sulfacetamide, sulfathiazole, sulfadiazine,
             sulfamethoxazole, sulfasalazine, sulfisoxazole and dapsone).

          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the
             Medical Sub- Investigator, could contraindicate the subject's participation in this
             study.

          -  Positive urine drug screen at screening.

          -  Positive testing for hepatitis B, hepatitis C, or HIV at screening.

          -  Positive urine pregnancy test at screening.(performed on all female subjects)

          -  Use of an investigational drug or participation in an investigational study within 30
             days prior to administration of the study medication.

          -  Donation of plasma ( 500 mL) within 7 days or donation of significant loss of whole
             blood (450 mL) within 56 days prior to administration of the study medication.

          -  History of significant alcohol abuse within six months of the screening visit or any
             indication of the regular use of more than two units of alcohol per day (1 Unit = 150
             mL of wine or 360 mL of beer or 45 ml of alcohol 40%)

          -  History of drug abuse or use of illegal drugs: Use of soft drugs (such as marijuana,
             pot) within 3 months of the screening visit or hard drugs (such as cocaine,
             phencyclidine [PCP] and crack) within 1 year of the screening visit.

          -  Subjects who have taken prescription medication within 14 days prior to administration
             of study medication or over the counter products within 7 days prior to administration
             of study medication, except for topical products without systemic absorption.

          -  Female subjects of childbearing potential having unprotected sexual intercourse with
             any non- sterile male partner (i.e. male who has not been sterilized by vasectomy for
             al least 6 months) within 14 days prior to study drug administration. The Acceptable
             methods of contraception are :

          -  Condom+ spermicide (within 14 days prior to study drug administration)

          -  Diaphragm + spermicide (within 14 days prior to study drug administration.

          -  Intrauterine contraceptive device (place al least 4 weeks prior to study drug
             administration)

          -  Subjects who have taken any drugs known to induce or inhibit hepatic drug metabolism
             within 30 days prior to administration of the study medication.

          -  (examples of inducers: barbiturates, carbamazepine, phenytoin,glucocorticoids,
             rifampin,rifabutin; examples of inhibitors: antidepressants, cimetidine, diltiazem,
             erythromycin, ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine)

          -  Subjects who have undergone clinically significant surgery within 4 weeks prior to the
             administration of the study medication.

          -  Any reason which, in the opinion of the investigator, would Prevent the subject from
             participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Masson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <last_update_submitted>June 16, 2011</last_update_submitted>
  <last_update_submitted_qc>June 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Alfred Elvin/ Director Biopharmaceutics</name_title>
    <organization>Par Pharmaceutical, Inc.</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Torsemide Tablets</keyword>
  <keyword>fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torsemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

